---
schema_version: "secwatch.filing_event.v1"
accession: "0001157523-22-000164"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2022-02-09T23:59:59+00:00"
generated_at: "2026-06-27T09:47:33.609768+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Teva reports FY 2021 revenue down 5% to $15.9B; GAAP EPS $0.38; Q4 GAAP loss

## Summary
- FY 2021 revenues $15.9B, down 5% YoY; GAAP diluted EPS $0.38 vs -$3.64 in 2020.
- Q4 2021 GAAP diluted EPS $(0.14); Non-GAAP diluted EPS $0.77.
- FY 2021 non-GAAP diluted EPS $2.58 (flat YoY); free cash flow $2.2B.
- 2022 outlook: revenue $15.6-$16.2B, non-GAAP EPS $2.40-$2.60, FCF $1.9-$2.2B.

## SEC filing metadata
- accession: 0001157523-22-000164
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2022-02-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/0001157523-22-000164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000115752322000164/a52576299.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001157523-22-000164
- JSON: https://secwatch.observer/filing/0001157523-22-000164.json
- Plain text: https://secwatch.observer/filing/0001157523-22-000164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.